相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin
Scott A. Reisman et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2014)
Myeloid Lineage-Specific Deletion of Antioxidant System Enhances Tumor Metastasis
Keiichiro Hiramoto et al.
CANCER PREVENTION RESEARCH (2014)
Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment
Yan-Yang Wang et al.
MOLECULAR CANCER (2014)
Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO
Anne Cleasby et al.
PLOS ONE (2014)
Topical Application of the Synthetic Triterpenoid RTA 408 Protects Mice from Radiation-Induced Dermatitis
Scott A. Reisman et al.
RADIATION RESEARCH (2014)
The Synthetic Triterpenoid CDDO-Methyl Ester Delays Estrogen Receptor-Negative Mammary Carcinogenesis in Polyoma Middle T Mice
Kim Tran et al.
CANCER PREVENTION RESEARCH (2012)
Molecular Pathways: Tumor-Infiltrating Myeloid Cells and Reactive Oxygen Species in Regulation of Tumor Microenvironment
Tangying Lu et al.
CLINICAL CANCER RESEARCH (2012)
A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
David S. Hong et al.
CLINICAL CANCER RESEARCH (2012)
Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease
Karen T. Liby et al.
PHARMACOLOGICAL REVIEWS (2012)
NRF2 and cancer: the good, the bad and the importance of context
Michael B. Sporn et al.
NATURE REVIEWS CANCER (2012)
The cytoprotective role of the Keap1-Nrf2 pathway
Liam Baird et al.
ARCHIVES OF TOXICOLOGY (2011)
Nrf2: control of sensitivity to carcinogens
Stephen L. Slocum et al.
ARCHIVES OF TOXICOLOGY (2011)
被撤回的出版物: INrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis (Retracted article. See vol. 21, pg. 503, 2014)
S. K. Niture et al.
CELL DEATH AND DIFFERENTIATION (2011)
The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis
Jason L. Townson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2011)
Novel Function of Transcription Factor Nrf2 as an Inhibitor of RON Tyrosine Kinase Receptor-mediated Cancer Cell Invasion
Amalraj Thangasamy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Genetic Disruption of KEAP1/CUL3 E3 Ubiquitin Ligase Complex Components is a Key Mechanism of NF-KappaB Pathway Activation in Lung Cancer
Kelsie L. Thu et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Gain of Nrf2 Function in Non-Small-Cell Lung Cancer Cells Confers Radioresistance
Anju Singh et al.
ANTIOXIDANTS & REDOX SIGNALING (2010)
Synthetic Triterpenoids Prolong Survival in a Transgenic Mouse Model of Pancreatic Cancer
Karen T. Liby et al.
CANCER PREVENTION RESEARCH (2010)
Nrf2: friend or foe for chemoprevention?
Thomas W. Kensler et al.
CARCINOGENESIS (2010)
Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung
Hironori Satoh et al.
CARCINOGENESIS (2010)
Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer
Srinivas Nagaraj et al.
CLINICAL CANCER RESEARCH (2010)
Increased cell migration and plasticity in Nrf2-deficient cancer cell lines
G. Rachakonda et al.
ONCOGENE (2010)
Oleanolic acid activates Nrf2 and protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent processes
Scott A. Reisman et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice
Melinda S. Yates et al.
CARCINOGENESIS (2009)
KEAP1 E3 Ligase-Mediated Downregulation of NF-κB Signaling by Targeting IKKβ
Dung-Fang Lee et al.
MOLECULAR CELL (2009)
NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer
John D. Hayes et al.
TRENDS IN BIOCHEMICAL SCIENCES (2009)
Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation
Wei Zou et al.
CANCER RESEARCH (2008)
Triterpenoid CDDO-methyl ester inhibits the janus-activated kinase-1 (JAK1)→Signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3
Rehan Ahmad et al.
CANCER RESEARCH (2008)
Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth
Tsutonm Ohta et al.
CANCER RESEARCH (2008)
Physiological significance of reactive cysteine residues of keap1 in determining Nrf2 activity
Tae Yamamoto et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent
Nicola Vannini et al.
MOLECULAR CANCER THERAPEUTICS (2007)
c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells
Wei Zou et al.
CANCER BIOLOGY & THERAPY (2007)
The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling
Xiaoyang Ling et al.
CANCER RESEARCH (2007)
Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-imidazolide
Rajesh K. Thimmulappa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-κB activation through direct inhibition of IκB kinase β
Mark M. Yore et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Triterpenoid CDDO-Me blocks the NF-κB pathway by direct inhibition of IKKβ on Cys-179
Rehan Ahmad et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The synthetic triterpenoid CDDO-imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells
Karen Liby et al.
CLINICAL CANCER RESEARCH (2006)
Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis
RK Thimmulappa et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
A synthetic triterpenoid, CDDO-Me, inhibits IκBα, kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor κB-regulated gene products in human leukemic cells
S Shishodia et al.
CLINICAL CANCER RESEARCH (2006)
Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells
M Konopleva et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Oleanolic acid and ursolic acid: Research perspectives
H Liu
JOURNAL OF ETHNOPHARMACOLOGY (2005)
Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress
AT Dinkova-Kostova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance
D Chauhan et al.
BLOOD (2004)
c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells
W Zou et al.
CANCER RESEARCH (2004)
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia
M Konopleva et al.
BLOOD (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
分享论文
